Sensei Biotherapeutics, Inc.
SNSE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.00 | 0.56 | -1.15 |
| FCF Yield | -30.09% | -54.77% | -3.57% | -2.35% |
| EV / EBITDA | -0.70 | -0.17 | -28.14 | -31.58 |
| Quality | ||||
| ROIC | -19.38% | -17.43% | -20.67% | -19.59% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.79 | 1.20 | 1.03 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 39.48% | 16.48% | -22.48% | -5.89% |
| Safety | ||||
| Net Debt / EBITDA | 1.76 | 2.04 | 0.98 | 0.81 |
| Interest Coverage | 808.50 | -520.60 | -559.54 | -486.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -853.78 | -1,083.00 | -412.94 |